Profile data is unavailable for this security.
About the company
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
- Revenue in USD (TTM)9.61bn
- Net income in USD1.62bn
- Incorporated1997
- Employees7.57k
- LocationBiogen Inc225 Binney StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (781) 464-2000
- Fax+1 (302) 636-5454
- Websitehttps://www.biogen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | 2.75bn | 322.29m | 12.09bn | 3.40k | 38.16 | 2.23 | 28.66 | 4.39 | 1.66 | 1.66 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Incyte Corp | 4.08bn | 32.48m | 13.56bn | 2.52k | 502.97 | 4.28 | 112.30 | 3.33 | 0.14 | 0.14 | 18.79 | 16.45 | 0.715 | 4.23 | 5.76 | 1,614,842.00 | 0.5698 | 9.07 | 0.7404 | 11.02 | 93.37 | 94.97 | 0.7969 | 13.68 | 1.82 | -- | 0.01 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Royalty Pharma plc | 2.27bn | 1.15bn | 15.55bn | 89.00 | 10.32 | 2.27 | 21.68 | 6.86 | 2.56 | 2.56 | 3.80 | 11.63 | 0.1337 | -- | 72.15 | 25,460,710.00 | 10.11 | 9.57 | 13.30 | 12.42 | -- | -- | 75.64 | 67.80 | -- | -- | 0.4258 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Viatris Inc | 15.05bn | -883.30m | 15.82bn | 38.00k | -- | 0.799 | 8.29 | 1.05 | -0.7389 | -0.7389 | 12.54 | 16.58 | 0.3219 | 2.23 | 4.94 | 396,013.20 | -1.89 | 0.0887 | -2.23 | 0.1061 | 42.49 | 40.29 | -5.87 | 0.2891 | 0.9615 | 2.37 | 0.443 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Biogen Inc | 9.61bn | 1.62bn | 23.03bn | 7.57k | 14.28 | 1.40 | 10.17 | 2.40 | 11.07 | 11.07 | 65.83 | 112.90 | 0.34 | 0.8604 | 4.58 | 1,269,155.00 | 5.71 | 12.53 | 7.01 | 14.83 | 75.59 | 83.04 | 16.80 | 26.93 | 0.8039 | 4.89 | 0.2778 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.09bn | -332.26m | 31.83bn | 2.10k | -- | 982.81 | -- | 15.20 | -2.62 | -2.62 | 16.52 | 0.2511 | 0.5208 | 3.57 | 8.41 | 997,521.40 | -8.26 | -26.56 | -11.31 | -32.77 | 85.37 | 83.66 | -15.86 | -94.26 | 2.69 | -1.36 | 0.9694 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 30 Sep 2024 | 16.32m | 11.20% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 16.03m | 11.01% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 8.57m | 5.88% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 7.34m | 5.04% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 5.04m | 3.46% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 4.26m | 2.92% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.61m | 2.48% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 2.93m | 2.01% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024 | 2.38m | 1.63% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.08m | 1.43% |
